Teva Pharmaceutical Industries Target of Unusually High Options Trading (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) was the target of some unusual options trading activity on Tuesday. Investors bought 34,288 call options on the company. This is an increase of 54% compared to the typical volume of 22,293 call options.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 31,766 shares of the company's stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $12.37, for a total transaction of $392,945.42. Following the completion of the sale, the chief accounting officer now directly owns 10,676 shares of the company's stock, valued at $132,062.12. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 31,766 shares of the company's stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $12.37, for a total transaction of $392,945.42. Following the completion of the sale, the chief accounting officer now directly owns 10,676 shares of the company's stock, valued at $132,062.12. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Mark Sabag sold 100,000 shares of the stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the completion of the sale, the executive vice president now directly owns 382,590 shares of the company's stock, valued at $5,172,616.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 390,738 shares of company stock valued at $5,132,766. Insiders own 0.62% of the company's stock.

Institutional Trading of Teva Pharmaceutical Industries

Several institutional investors and hedge funds have recently bought and sold shares of TEVA. Harel Insurance Investments & Financial Services Ltd. lifted its stake in Teva Pharmaceutical Industries by 184,642.3% during the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 27,711,340 shares of the company's stock valued at $282,656,000 after acquiring an additional 27,696,340 shares during the period. Sound Shore Management Inc CT purchased a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at approximately $80,791,000. State Street Corp increased its holdings in shares of Teva Pharmaceutical Industries by 29.4% during the 1st quarter. State Street Corp now owns 19,564,828 shares of the company's stock valued at $172,988,000 after purchasing an additional 4,441,883 shares in the last quarter. Exor Capital LLP increased its holdings in Teva Pharmaceutical Industries by 30.3% in the 4th quarter. Exor Capital LLP now owns 15,008,389 shares of the company's stock worth $93,903,000 after acquiring an additional 3,486,202 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. increased its holdings in Teva Pharmaceutical Industries by 14.4% in the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 27,059,540 shares of the company's stock worth $276,000,000 after acquiring an additional 3,413,100 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Performance

TEVA stock traded down $0.22 during trading on Tuesday, reaching $13.98. The company had a trading volume of 10,199,870 shares, compared to its average volume of 10,783,861. The firm has a 50-day simple moving average of $13.33 and a 200-day simple moving average of $11.09. The company has a market cap of $15.67 billion, a price-to-earnings ratio of -29.73, a price-to-earnings-growth ratio of 1.65 and a beta of 1.05. The company has a debt-to-equity ratio of 2.23, a quick ratio of 0.69 and a current ratio of 1.02. Teva Pharmaceutical Industries has a twelve month low of $7.09 and a twelve month high of $14.47.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, January 31st. The company reported $0.98 EPS for the quarter, topping analysts' consensus estimates of $0.73 by $0.25. The company had revenue of $4.46 billion during the quarter, compared to analysts' expectations of $3.97 billion. Teva Pharmaceutical Industries had a negative net margin of 3.33% and a positive return on equity of 34.90%. As a group, sell-side analysts expect that Teva Pharmaceutical Industries will post 2.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on TEVA shares. The Goldman Sachs Group increased their price objective on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a "neutral" rating in a research note on Monday, February 5th. Barclays increased their price objective on shares of Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the company an "overweight" rating in a research report on Monday, February 5th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research report on Thursday, February 1st. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from an "underweight" rating to a "neutral" rating and set a $14.00 price objective for the company in a research report on Friday, March 8th. Finally, Piper Sandler upgraded shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and raised their target price for the stock from $12.00 to $19.00 in a report on Monday, February 12th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $13.78.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.